NCT05759728 2026-01-13
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
Carina Biotech Limited
Phase 1/2 Recruiting
Clinical Trials
16 trialsNCT06008119 2025-09-18
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT04867525 2025-05-01
AZURITE
iOMEDICO AG
Active not recruiting
NCT05243862 2025-03-18
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Treos Bio Limited
Phase 2 Active not recruiting
NCT05584137 2024-10-15
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Shanghai Henlius Biotech
Phase 2 Terminated
NCT03439462 2024-01-02
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT04169347 2023-07-27
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
Phase 2 Unknown
NCT01483027 2022-03-29
EPOCH
Boston Scientific Corporation
Phase NA Completed
NCT03531632 2022-02-08
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
MacroGenics
Phase 1/2 Completed
NCT03556956 2020-12-08
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
AB Science
Phase 2/3 Completed
NCT01571284 2018-04-17
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Sanofi
Phase 3 Completed
NCT01882868 2017-03-14
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
Phase 2 Completed
NCT01959061 2017-03-13
TACE
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 4 Unknown
NCT01955629 2016-04-18
AMOR
Sanofi
Phase 1/2 Terminated
NCT02085005 2014-11-18
Drop and Go
Sanofi
Phase 2 Withdrawn